Alexza Pharmaceuticals
Focused on multiple clinical stage therapeutics all leveraging the proprietary Staccato™ system for rapid delivery of drugs to the CNS to treat acute agitation, migraine, breakthrough pain, panic attacks, and insomnia

Alnara Pharmaceuticals
Focused on developing non-systematic protein therapeutics for the treatment of metabolic diseases. Acquired by Eli Lilli in July 2010 (Exited)

Amicus Therapeutics
Developing clinical pipeline of oral small molecule chaperone therapeutics to treat lysosomal storage disease, including Fabry, Gaucher, and Pompe, as well as other genetic diseases

Anaptys
Developing novel anitbody therapeutics using proprietary somatic hypermutation platform

Array BioPharma
Developing a clinical pipeline of oral small molecule drugs to treat cancer and inflammatory diseases (Exited)

Cadence Pharmaceuticals
Commercial stage, hospital-focused company marketing OFIRMEV™ for acute pain

Calistoga Pharmaceuticals
Clinical stage company developing small molecule portfolio in the PI-3 kinase family to treat cancer and inflammation. Acquired by Gilead in April 2011 (Exited)

Calixa Therapeutics
Clinical stage, infectious disease company in clinical trials with a potent antibiotic to treat gram negative infections, including those from the hard-to-treat Pseudomonas. Acquired by Cubist in December 2009 (Exited)

Cerexa
Acquired by Forest Labs (FRX). Now a wholly-owned subsidiary developing Ceftaroline™ and other novel anti-infectives for life threatening bacterial infections. Acquired by Forest in December 2009 (Exited)

Chimerix
Clinical stage company with pipeline of anti-viral assets to treat smallpox, HPV, CMV, HIV leveraging proprietary platform technology to improve oral drug delivery

Clovis Oncology
Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets.

Collegium Pharmaceutical
Specialty pharmaceutical company focused on the development of proprietary, later stage pharmaceutical products in pain and respiratory fields

Cotherix
Developed Ventavis™ for pulmonary arterial hypertension. Acquired by Actelion in November 2006 (Exited)

CV Therapeutics
Developed Ranexa™ for chronic angina and clinical pipeline of small molecule therapeutics to treat cardiovascular disease (Exited)

Geron
Anti-cancer drugs and cancer vaccines targeting the enzyme telomerase as well as developing embryonic stem cell-based therapeutics (Exited)

Kalidex Pharmaceuticals
Kalidex is developing next-generation, broad-spectrum antibiotics for the treatment of serious infections

Marcadia Biotech
Acquired by Roche in December 2010. Clinical stage company developing pipeline of peptide therapeutics to treat metabolic diseases. Acquired by Roche in December 2010 (Exited)

Nuon Therapeutics
Clinical stage company developing Tranilast® to treat gout and other indications

OraPharma
Developed Arrestin™ for periodontal diseases (Exited)

Portola Pharmaceuticals
Clinical stage company developing next-generation antithrombotic drugs, including oral Factor Xa inhibitor, Betrixaban™, and an ADP receptor antagonist, for acute and chronic cardiovascular disease

QuatRx
Clinical stage company preparing NDA for Osphena™ for post-menopause vaginal atrophy

Rempex Pharmaceuticals
Rempex is developing the next generation of antibiotics against resistant Gram negative bacteria. These therapies will address the growing unmet need of infections by bacteria that are resistant to all current antibiotics

Rigel
Developing small molecule drugs for inflammatory/autoimmune diseases, cancer, viral and metabolic diseases (Exited)

Silence Therapeutics (formerly Intradigm)
Clinical stage company developing proprietary platform of novel, systemically delivered RNAi therapeutics

SilverGate Pharmaceuticals
A pharmaceutical company that is focused on developing pediatric formulations of off-patent adult drugs

Stromedix
Clinical stage company developing antibody to treat fibrosis associated with renal transplantation

Tobira Therapeutics
Clinical stage HIV company developing best in class CCR5 therapeutics

Trubion Pharmaceuticals
Developing small modulatory immunoparticles (SMIPs) for CD20, CD37 and other high value targets. Acquired by Emergent in April 2010 (exited)

Tularik
Engaged in the discovey and development of a broad range of novel and superior oral available medicines that act through the regulation of gene expression (Exited)

VentiRx Pharmaceuticals
Clinical stage company developing small molecule portfolio in the TLR family to treat cancer, infectious, repiratory and autoimmune diseases

ViroPharma
Developing novel therapies to treat infectious disease including its marketed product Vancocin for treatment of colitis from Clostridium difficile (exited)

Vivus
Portfolio to treat obesity and sexual health (Exited)

XenoPort
Clinical portfolio including Solzira™ for restless legs syndrome and neuropathic pain as well as pipeline of drugs to treat GERD, Parkinsons and migraine, all developed using its proprietary platform technology to improve bioavailability (Exited)

Zymogenetics
Focused on developing a pipeline of therapeutic proteins including Recothrom™ for hemostasis (Exited)

Ascension Orthopedics
Leading orthopedics company addressing unmet needs in the extremeties field (Exited)

Barosense
Developing trans-oral medical devices and procedures for addressing obesity and its co-morbidities

BARRX Medical
Provides solutions for Barrett's esophagus, a precancerous change to the thin layer of tissue lining the esophagus

Calibra Medical
Developing a mechanical disposable insulin pump

Calypso Medical
Developed and selling a system to guide precise targeting of radiation therapy (Exited)

Cardiac Dimensions
Developing novel interventional tools for the treatment of mitral valve regurgitation

CVRX
Developing stimulation-based products to treat hypertension and other chronic conditions

EBR Systems
Pursuing novel approaches in cardiac rhythm management

FlowCardia
Focused on the treatment of chronic total occlusions in coronary artery and peripheral vascular disease (Exited)

Glaukos
Clinical stage ophthalmology company developing treatments for glaucoma

InnerPulse
Developing a disruptive interventional technology platform for cardiac rhythm management devices

Moximed
Dedicated to Improving the standard of care for patients with Osteoarthritis

PatientKeeper
Market leader in mobile HCIT solutions for healthcare providers

PowerVision
Developing an accommodating intraocular lens implant for the correction of Presbyopia

Primaeva
Early stage medical device company developing a skin tightening and rejuvenation dermatological device (Exited)

Xoft
Developing a family of micro-miniature x-ray source based medical devices to address various types of cancers

Zeltiq Aesthetics
Commercializing new technologies for non-invasive fat layer reduction

Zonare
A paradigm-shifting ultrasound company